General
Preferred name
GABOXADOL
Synonyms
THIP HYDROCHLORIDE ()
THIP ()
GABOXADOL HYDROCHLORIDE ()
4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol ()
Gaboxadol (hydrochloride) ()
Lu 02-030 (hydrochloride) ()
THIP (hydrochloride) ()
LU-02030 ()
NSC-759585 ()
MK-0928 ()
LU 02-030 ()
LU-02-030 ()
P&D ID
PD008923
CAS
85118-33-8
64603-91-4
Tags
available
drug candidate
drug
Drug indication
Discovery agent
Insomnia
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Gaboxadol hydrochloride (Lu 02-030 hydrochloride) is a potent agonist of the GABAA receptor and an antagonist of GABAC receptors (IC50=25 ¦ÌM). Gaboxadol hydrochloride displays a partial agonist efficacy on subunit ¦Á1¦Â2¦Ã2 with an ED50 value of 143 ¦ÌM, a full agonist efficacy at ¦Á5 subunit (ED50=28-129 ¦ÌM) and a superagonist efficacy at ¦Á4¦Â3¦Ä (ED50=6 ¦ÌM). Gaboxadol hydrochloride is a non-opioid agent[1][2].
DESCRIPTION
GABAA agonist, with some preference for δ subunit-containing channels .
(GtoPdb)
DESCRIPTION
GABA-T inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
GABA-A receptor agonist, with some GABA-C receptor agonist activity
(LOPAC library)
DESCRIPTION
GABAA agonist
(Tocriscreen Total)
DESCRIPTION
GABAA agonist
(Tocriscreen Plus)
DESCRIPTION
Gaboxadol hydrochloride acts as an antagonist of Gamma-aminobutyric-acid A receptor.
(Enamine Bioactive Compounds)
DESCRIPTION
Gaboxadol is a GABA agonist. It was a non-opioid analgesic and a novel type of hypnotic. It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-Larsen. It is an experimental sleep aid drug developed by Lundbeck and Merck. It was used as an analgesic and anxiolytic, as well as a treatment for tardive dyskinesia, Huntington's disease, Alzheimer's disease, and spasticity. It was in clinic phase 3 trials, but now it was terminated.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
25
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
Ki Database
LOPAC library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
56
Molecular Weight
140.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
0
Ring Count
2
Aromatic Ring Count
1
cLogP
0.03
TPSA
58.29
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Selectivity
GABA-A
Primary Target
GABAA Receptors
MOA
Agonist
GABA(A) Receptor Partial Agonists
Selective GABAA-delta agonist
benzodiazepine receptor agonist
Member status
member
Target
GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRD, GABRR1, GABRR2, GABRR3
GABA Receptor
Therapeutic Class
Hypnotics and Sedatives
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Solubility
Ethanol: 0.91 mg/mL
Source data
